Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with...

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Mutations in epidermal growth factor receptor (EGFR) are key drivers in non-small cell lung cancer (NSCLC).
• EGFR mutations correlate with responsiveness to targeted therapies such as Iressa.
• Noninvasive imaging of EGFR expression is crucial for personalized NSCLC treatment.

Purpose of the Study:

• To evaluate morpholino-[(124)I]IPQA as a positron emission tomography (PET) imaging agent for detecting diverse EGFR mutations in NSCLC.
• To assess the in vitro and in vivo feasibility of this radiotracer for visualizing EGFR expression in NSCLC models.

Main Methods:

• In vitro studies involved radiotracer accumulation and washout assays in NSCLC cell lines with varying EGFR expression levels.
• In vivo studies utilized microPET imaging in subcutaneous tumor xenografts derived from NSCLC cell lines.
• Morpholino-[(124)I]IPQA derivative was synthesized and evaluated for its binding and retention characteristics.

Main Results:

• The morpholino-[(131)I]IPQA derivative demonstrated rapid accumulation and sustained retention in EGFR-mutant NSCLC cell lines (L858R, E746-A750 del) in vitro.
• MicroPET imaging successfully visualized EGFR activity in xenografts of L858R and E746-A750 del mutant tumors, but not in control xenografts.
• Differential uptake of the radiotracer was observed across different EGFR mutant tumors.

Conclusions:

• Morpholino-[(124)I]IPQA shows potential as an in vivo PET imaging probe for EGFR mutants in NSCLC.
• Further structural modifications are needed to enhance water solubility and reduce hepatobiliary clearance of the tracer.
• This imaging agent could facilitate patient selection for EGFR-targeted tyrosine kinase inhibitor therapy in NSCLC.